DK200701150A - Recombinant pox virus and vaccine against herpes virus containing this - Google Patents

Recombinant pox virus and vaccine against herpes virus containing this Download PDF

Info

Publication number
DK200701150A
DK200701150A DK200701150A DKPA200701150A DK200701150A DK 200701150 A DK200701150 A DK 200701150A DK 200701150 A DK200701150 A DK 200701150A DK PA200701150 A DKPA200701150 A DK PA200701150A DK 200701150 A DK200701150 A DK 200701150A
Authority
DK
Denmark
Prior art keywords
virus
herpesvirus
dna
recombinant
vaccine
Prior art date
Application number
DK200701150A
Other languages
Danish (da)
Inventor
Paoletti Enzo
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/502,834 external-priority patent/US5338683A/en
Application filed by Health Research Inc filed Critical Health Research Inc
Priority to DK200701150A priority Critical patent/DK200701150A/en
Publication of DK200701150A publication Critical patent/DK200701150A/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (51)

1. Rekombinant poxvirus, kendetegnet ved, at det, i et ikke-essentielt område af poxvirusgenomet, indeholder DNA fra equint herpesvirus.1. Recombinant poxvirus, characterized in that, in a non-essential region of the poxvirus genome, it contains DNA from equine herpesvirus. 2. Rekombinant poxvirus ifølge krav 1, kendetegnet ved, at DNAen koder for et equint herpesvirus-glycoprotein.Recombinant poxvirus according to claim 1, characterized in that the DNA encodes an equine herpesvirus glycoprotein. 3. Rekombinant poxvirus ifølge krav 2, kendetegnet ved, at det equine herpesvirus-glycoprotein er equint herpesvirus -glycoprotein gpl3 .Recombinant poxvirus according to claim 2, characterized in that the equine herpesvirus glycoprotein is the equine herpesvirus glycoprotein gp1. 4. Rekombinant poxvirus ifølge krav 2, kendetegnet ved, at det equine herpesvirus-glycoprotein er equint herpesvirus-glycoprotein gpi4.Recombinant poxvirus according to claim 2, characterized in that the equine herpesvirus glycoprotein is the equine herpesvirus glycoprotein gpi4. 5. Rekombinant poxvirus ifølge krav 1, kendetegnet ved, at DNAen koder for to equine herpesvirus-glycoproteiner,Recombinant poxvirus according to claim 1, characterized in that the DNA encodes two equine herpesvirus glycoproteins, 6. Rekombinant poxvirus ifølge krav 5, kendetegnet ved, at de equine herpesvirus-glycoproteiner er equint herpesvirus-glycoprotein gpl3 og equint herpesvirus-glycoprotein gpl4.Recombinant poxvirus according to claim 5, characterized in that the equine herpesvirus glycoproteins are equine herpesvirus glycoprotein gpl3 and equine herpesvirus glycoprotein gpl4. 7. Rekombinant poxvirus ifølge krav 1, kendetegnet ved, at DNAen er udtrykt i en vært ved produktionen af et equint herpesvirus-glycoprotein. δ. Rekombinant poxvirus ifølge krav 7, kendetegnet ved, at det equine herpesvirus-glycoprotein er equint herpesvirus-glycoprotein gpl3.Recombinant poxvirus according to claim 1, characterized in that the DNA is expressed in a host in the production of an equine herpesvirus glycoprotein. δ. Recombinant poxvirus according to claim 7, characterized in that the equine herpesvirus glycoprotein is the equine herpesvirus glycoprotein gp1. 9. Rekombinant poxvirus ifølge krav 7, kendetegnet ved, at det equine herpesvirus-glycoprotein er equint herpesvirus-glycoprotein gpl4.Recombinant poxvirus according to claim 7, characterized in that the equine herpesvirus glycoprotein is the equine herpesvirus glycoprotein gp1. 10. Rekombinant poxvirus ifølge krav 1, kendetegnet ved, at DNAen er udtrykt i en vært ved produktionen af to equine herpesvirus-glycoproteiner.Recombinant poxvirus according to claim 1, characterized in that the DNA is expressed in a host in the production of two equine herpesvirus glycoproteins. 11. Rekombinant poxvirus ifølge krav 10, kendetegnet ved, at de equine herpesvirus-glycoproteiner er equint herpesvirus-glycoprotein gpl3 og equint herpesvirus-glycoprotein gpl4.Recombinant poxvirus according to claim 10, characterized in that the equine herpesvirus glycoproteins are equine herpesvirus glycoprotein gpl3 and equine herpesvirus glycoprotein gpl4. 12. Rekombinant poxvirus ifølge krav 1, kendetegnet ved, at poxviruset er et vacciniavirus.Recombinant pox virus according to claim 1, characterized in that the pox virus is a vaccinia virus. 13. Rekombinant poxvirus ifølge krav l, kendetegnet ved, at poxviruset er en avipox virus.Recombinant pox virus according to claim 1, characterized in that the pox virus is an avipox virus. 14. Rekombinant poxvirus ifølge krav 13, kendetegnet ved, at avipoxviruset er valgt blandt fjerkræpoxvirus og kanariepoxvirus.Recombinant pox virus according to claim 13, characterized in that the avipox virus is selected from poultry pox virus and canary epox virus. 15. Rekombinant poxvirus ifølge krav 1, kendetegnet ved, at DNAen introduceres i poxvirussen ved rekombination.Recombinant pox virus according to claim 1, characterized in that the DNA is introduced into the pox virus by recombination. 16. Rekombinant poxvirus, kendetegnet ved, at det, indeholder DNA fra equint herpesvirus og en promoter til ud-trykkelse af DNAen.16. Recombinant pox virus, characterized in that it contains DNA from equine herpesvirus and a promoter for expressing the DNA. 17. Vaccine til inducering af et immunologisk respons i et med vaccinen inokuleret værtsdyr, kendetegnet ved, at vaccinen omfatter et bærestof og et rekombinant poxvirus, der i et ikke-essentielt område indeholder DNA fra equint herpesvirus.Vaccine for inducing an immunological response in a vaccine-inoculated host animal, characterized in that the vaccine comprises a carrier and a recombinant poxvirus containing, in a non-essential region, DNA from equine herpesvirus. 18. Vaccine ifølge krav 17, kendetegnet ved, at DNAen koder for og udtrykker et equint herpesvirus glycoprotein.Vaccine according to claim 17, characterized in that the DNA encodes and expresses an equine herpesvirus glycoprotein. 19. Vaccine ifølge krav 18, kendetegnet ved, at det equine herpesvirus-glycoprotein er equint herpesvirus -glycoprotein gpl3,Vaccine according to claim 18, characterized in that the equine herpesvirus glycoprotein is equine herpesvirus glycoprotein gp1, 20. Vaccine ifølge krav 18, kendetegnet ved, at det equine herpesvirus-glycoprotein er equint herpesvirus -glycoprotein gpl4.Vaccine according to claim 18, characterized in that the equine herpesvirus glycoprotein is the equine herpesvirus glycoprotein gp1. 21. Vaccine ifølge krav 17, kendetegnet ved, at DNAen koder for og udtrykker to equine herpesvirus glycopro-teiner.Vaccine according to claim 17, characterized in that the DNA encodes and expresses two equine herpesvirus glycoproteins. 22. Vaccine ifølge krav 21, kendetegnet ved, at de equine herpesvirus-glycoproteiner er equint herpesvirus-glycoprotein gpl3 og equint herpesvirus-glycoprotein gpl4.Vaccine according to claim 21, characterized in that the equine herpesvirus glycoproteins are equine herpesvirus glycoprotein gpl3 and equine herpesvirus glycoprotein gpl4. 23. Vaccine ifølge krav 17, kendetegnet ved, at poxviru-set er et vacciniavirus.Vaccine according to claim 17, characterized in that the poxvirus is a vaccinia virus. 24. Vaccine ifølge krav 17, kendetegnet ved, at poxviru-set er en avipoxvirus.Vaccine according to claim 17, characterized in that the poxvirus is an avipox virus. 25. Vaccine ifølge krav 24, kendetegnet ved, at avipox-viruset er valgt blandt fjerkræpoxvirus og kanariepoxvi-rus.Vaccine according to claim 24, characterized in that the avipox virus is selected from poultry pox virus and canary pox virus. 26. Vaccine ifølge krav 17, kendetegnet ved, at DNAen introduceres i poxvirussen ved rekombination.Vaccine according to claim 17, characterized in that the DNA is introduced into the pox virus by recombination. 27. Rekombinant poxvirus, kendetegnet ved, at det, i et ikke-essentielt område af poxvirusgenomet, indeholder DNA fra herpesvirus.27. Recombinant poxvirus, characterized in that, in a non-essential region of the poxvirus genome, it contains DNA from herpes virus. 28. Rekombinant poxvirus ifølge krav 27, kendetegnet ved, at herpesviruset tilhører en herpesvirus- underfamilie valgt blandt a-herpesvirus, β-herpesvirus og γ-herpesvirus.Recombinant pox virus according to claim 27, characterized in that the herpes virus belongs to a herpes virus subfamily selected from α-herpes virus, β-herpes virus and γ-herpes virus. 29. Rekombinant poxvirus ifølge krav 28, kendetegnet ved, at herpesviruset tilhører herpesvirus equi, pseudo-rabies virus, herpes simplex virus, bovint herpesvirus, felint herpesvirus, Epstein-Barr virus og humant cytomegalovirus .Recombinant pox virus according to claim 28, characterized in that the herpes virus belongs to the herpes virus equi, pseudo-rabies virus, herpes simplex virus, bovine herpes virus, feline herpes virus, Epstein-Barr virus and human cytomegalovirus. 30. Rekombinant poxvirus ifølge krav 27, kendetegnet ved, DNAen koder for et herpesvirus-glycoprotein.Recombinant poxvirus according to claim 27, characterized in that the DNA encodes a herpesvirus glycoprotein. 31. Rekombinant poxvirus ifølge krav 30, kendetegnet ved, at herpesvirus-glycoproteinet vælges blandt equint herpesvirus gpl3, equint herpesvirus gpl4, equint herpesvirus gD, equint herpesvirus gp63, equint herpesvirus gE, pseudorabies virus gp50, pseudorabies virus gpll, pseudorabies virus gpIII, pseudorabies virus gpl, herpes simplex virus gB, herpes simplex virus gC, herpes simplex virus gD, bovint herpesvirus gi, felint herpesvirus gB, Epstein-Barr virus gp220, Epstein-Barr virus gp340, Epstein-Barr virus gB, Epstein-Barr virus gH og humant cytomegalovirus gB.Recombinant poxvirus according to claim 30, characterized in that the herpesvirus glycoprotein is selected from equine herpesvirus gpl3, equint herpesvirus gpl4, equint herpesvirus gD, equint herpesvirus gp63, equint herpesvirus gE, pseudorabies virus gp50, pseudorabies psp. virus gpl, herpes simplex virus gB, herpes simplex virus gC, herpes simplex virus gD, bovine herpes virus gi, feline herpes virus gB, Epstein-Barr virus gp220, Epstein-Barr virus gp340, Epstein-Barr virus gB, Epstein-Barr virus gH and human cytomegalovirus gB. 32. Rekombinant poxvirus ifølge krav 27, kendetegnet ved, at DNAen koder for mindst to herpesvirus-glycoproteiner.Recombinant poxvirus according to claim 27, characterized in that the DNA encodes at least two herpesvirus glycoproteins. 33. Rekombinant poxvirus ifølge krav 27, kendetegnet ved, DNAen er udtrykt i en vært ved produktionen af et herpesvirus-glycoprotein.Recombinant poxvirus according to claim 27, characterized in that the DNA is expressed in a host in the production of a herpesvirus glycoprotein. 34. Rekombinant poxvirus ifølge krav 33, kendetegnet ved, at herpesvirus-glycoproteinet vælges blandt equint herpesvirus gpl3, equint herpesvirus gp!4, equint herpesvirus gD, equint herpesvirus gp63, equint herpesvirus gE, pseudorabies virus gp50, pseudorabies virus gpll, pseudorabies virus gpIII, pseudorabies virus gpl, herpes simplex virus gB, herpes simplex virus gC, herpes simplex virus gD, bovint herpesvirus gl, felint herpesvirus gB, Epstein-Barr virus gp220, Epstein-Barr virus gp340, Epstein-Barr virus gB, Epstein-Barr virus gH og humant cytomegalovirus gB.Recombinant poxvirus according to claim 33, characterized in that the herpesvirus glycoprotein is selected from equine herpesvirus gpl3, equint herpesvirus gp4, equint herpesvirus gD, equint herpesvirus gp63, equint herpesvirus gE, pseudorabies virus gp50, pseudorabies virus gp50, pseudorabies virus gp50, , pseudorabic virus gpl, herpes simplex virus gB, herpes simplex virus gC, herpes simplex virus gD, bovine herpes virus gl, feline herpes virus gB, Epstein-Barr virus gp220, Epstein-Barr virus gp340, Epstein-Barr virus gB, Epstein-Barr virus gH and human cytomegalovirus gB. 35. Rekombinant poxvirus ifølge krav 27, kendetegnet ved, at DNAen er udtrykt i en vært ved produktionen af mindst to herpesvirus-glycoproteiner.Recombinant poxvirus according to claim 27, characterized in that the DNA is expressed in a host in the production of at least two herpesvirus glycoproteins. 36. Rekombinant poxvirus ifølge krav 27, kendetegnet ved, at poxviruset er et vacciniavirus.Recombinant pox virus according to claim 27, characterized in that the pox virus is a vaccinia virus. 37. Rekombinant poxvirus ifølge krav 27, kendetegnet ved, at poxviruset er et avipoxvirus.The recombinant pox virus according to claim 27, characterized in that the pox virus is an avipox virus. 38. Rekombinant poxvirus ifølge krav 37, kendetegnet ved, at avipoxviruset er valgt blandt fjerkræpoxvirus og kanariepoxvirus.The recombinant pox virus according to claim 37, characterized in that the avipox virus is selected from poultry pox virus and canary epox virus. 39. Rekombinant poxvirus ifølge krav 27, kendetegnet ved, at DNAen introduceres i poxvirussen ved rekombination.The recombinant pox virus according to claim 27, characterized in that the DNA is introduced into the pox virus by recombination. 40. Rekombinant poxvirus, kendetegnet ved, at det, indeholder DNA fra herpesvirus og en promoter til udtrykkel-se af DNAen.40. Recombinant pox virus, characterized in that it contains DNA from herpes virus and a promoter for expression of the DNA. 41. Vaccine til inducering af et immunologisk respons i et med vaccinen inokuleret værtsdyr, kendetegnet ved, at vaccinen omfatter et bærestof og et rekombinant poxvi- irus, der i et ikke-essentielt område indeholder DNA fra herpesvirus.A vaccine for inducing an immunological response in a vaccine-inoculated host animal, characterized in that the vaccine comprises a carrier and a recombinant poxvirus containing in a non-essential region DNA from the herpes virus. 42. Vaccine ifølge krav 41, kendetegnet ved, at herpes-viruset tilhører en herpesvirus-underfamilie valgt blandt a-herpesvirus, β-herpesvirus og γ-herpesvirus,The vaccine of claim 41, characterized in that the herpes virus belongs to a herpesvirus subfamily selected from α-herpesvirus, β-herpesvirus and γ-herpesvirus. 43. Vaccine ifølge krav 42, kendetegnet ved, at herpes-viruset er valgt blandt herpesvirus equi, pseudorabies virus, herpes simplex virus, bovint herpesvirus, felint herpesvirus, Epstein-Barr virus og humant cytomegalovirus .The vaccine according to claim 42, characterized in that the herpes virus is selected from the herpes virus equi, pseudorabies virus, herpes simplex virus, bovine herpes virus, feline herpes virus, Epstein-Barr virus and human cytomegalovirus. 44. Vaccine ifølge krav 41, kendetegnet ved, at DNAen koder for og udtrykker et herpesvirus-glycoprotein.A vaccine according to claim 41, characterized in that the DNA encodes and expresses a herpes virus glycoprotein. 45. Vaccine ifølge krav 44, kendetegnet ved, at herpesvirus -glycop ro teinet er valgt blandt herpesvirus equi gpl3, herpesvirus equi gpl4, herpesvirus equi gD, herpesvirus equi gp63, herpesvirus equi gE, pseudorabies virus gp50, pseudorabies virus gpll, pseudorabies virus gpIII, pseudorabies virus gpl, herpes simplex virus gB, herpes simplex virus gC, herpes simplex virus gD, bovint herpesvirus gi, felint herpesvirus gB, Epstein-Barr virus gp220, Epstein-Barr virus gp340, Epstein-Barr virus gB, Epstein-Barr virus gH og humant cytomegalovirus gB.The vaccine of claim 44, characterized in that the herpesvirus glycoproin is selected from the herpesvirus equi gpl3, herpesvirus equi gpl4, herpesvirus equi gD, herpesvirus equi gp63, herpesvirus equi gE, pseudorabies virus gp50, pseudorabies virus gp50, pseudorabies virus gp50 , pseudorabic virus gpl, herpes simplex virus gB, herpes simplex virus gC, herpes simplex virus gD, bovine herpes virus gi, feline herpes virus gB, Epstein-Barr virus gp220, Epstein-Barr virus gp340, Epstein-Barr virus gB, Epstein-Barr virus gH and human cytomegalovirus gB. 46. Vaccine ifølge krav 41, kendetegnet ved, at DNAen koder for og udtrykker mindst to herpesvirusglycoprotei-ner.The vaccine of claim 41, characterized in that the DNA encodes and expresses at least two herpesvirus glycoproteins. 47. Vaccine ifølge krav 41, kendetegnet ved, at poxviru-set er et vacciniavirusThe vaccine of claim 41, characterized in that the poxvirus is a vaccinia virus 48. Vaccine ifølge krav 41, kendetegnet ved, at poxviru-set er et avipoxvirus.The vaccine of claim 41, characterized in that the poxvirus is an avipox virus. 49. Vaccine ifølge krav 48, kendetegnet ved, at avipox-viruset er valgt blandt fjerkræpoxvirus og kanariepoxvi-rus.The vaccine according to claim 48, characterized in that the avipox virus is selected from poultry pox virus and canary pox virus. 50. Vaccine ifølge krav 41, kendetegnet ved, at DNAen introduceres i poxvirussen ved rekombination.Vaccine according to claim 41, characterized in that the DNA is introduced into the pox virus by recombination. 51. Sæt af vacciner til inducering af et immunologisk respons på et patogen i en mor og hendes nyfødte afkom, samtidig med at maternel immunitet i det nyfødte afkom undgås, kendetegnet ved, at det omfatter en vaccine til moderen omfattende et rekombinant poxvirus indeholdende DNA fra en ikke-pox-kilde i et ikke-essentielt område af poxvirus-genomet, idet DNAen koder for et første antigen fra et patogen fra moderen og hendes nyfødte afkom, og en vaccine til det nyfødte afkom omfattende det rekombi-nante poxvirus indeholdende DNA fra en ikke-pox-kilde i et ikke-essentielt område af poxvirusgenomet, idet DNAen koder for et andet antigen fra det samme patogen, hvil ket andet antigen er forskelligt fra antigenet anvendt til inducering af det immunologiske respons i moderen.51. Set of vaccines for inducing an immunological response to a pathogen in a mother and her newborn progeny while avoiding maternal immunity in the newborn progeny, characterized in that it comprises a vaccine for the mother comprising a recombinant poxvirus containing DNA from a non-pox source in a non-essential region of the poxvirus genome, the DNA encoding a first antigen from a mother and her newborn progeny pathogen, and a newborn progeny vaccine comprising the recombinant poxvirus containing DNA from a non-pox source in a non-essential region of the pox virus genome, the DNA encoding a different antigen from the same pathogen, which other antigen is different from the antigen used to induce the immunological response in the mother. 52. Sæt af vacciner til inducering af et immunologisk respons på et patogen i en mor og hendes nyfødte afkom, samtidig med at maternel immunitet i det nyfødte afkom undgås, kendetegnet ved, at det omfatter en vaccine til moderen omfattende et rekombinant første poxvirus indeholdende DNA fra en ikke-pox-kilde i et ik-ke-essentielt område af det første poxvirus-genom, idet DNAen koder for et antigen fra et patogen fra moderen og hendes nyfødte afkom, og en vaccine til det nyfødte afkom omfattende et rekombinant andet poxvirus indeholdende DNA fra en ikke-pox-kilde i et ikke-essentielt område af det andet poxvirus-genom, hvilken DNA koder for et antigen fra det samme patogen.52. Set of vaccines to induce an immunological response to a pathogen in a mother and her newborn progeny while avoiding maternal immunity in the newborn progeny, characterized in that it comprises a vaccine for the mother comprising a recombinant first poxvirus containing DNA from a non-pox source in a non-essential region of the first poxvirus genome, the DNA encoding an antigen from a pathogen of the mother and her newborn progeny, and a vaccine for the newborn progeny comprising a recombinant second poxvirus containing DNA from a non-pox source in a non-essential region of the second poxvirus genome, which encodes an antigen from the same pathogen.
DK200701150A 1989-04-17 2007-08-13 Recombinant pox virus and vaccine against herpes virus containing this DK200701150A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DK200701150A DK200701150A (en) 1989-04-17 2007-08-13 Recombinant pox virus and vaccine against herpes virus containing this

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US33900489A 1989-04-17 1989-04-17
US33900489 1989-04-17
US39448889A 1989-08-16 1989-08-16
US39448889 1989-08-16
US07/502,834 US5338683A (en) 1981-12-24 1990-04-04 Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US50283490 1990-04-04
DK174391 1991-10-15
DK199101743A DK176464B1 (en) 1989-04-17 1991-10-15 Recombinant pox virus and vaccine against herpes virus containing this
DK200701150A DK200701150A (en) 1989-04-17 2007-08-13 Recombinant pox virus and vaccine against herpes virus containing this
DK200701150 2007-08-13

Publications (1)

Publication Number Publication Date
DK200701150A true DK200701150A (en) 2007-08-13

Family

ID=39015732

Family Applications (1)

Application Number Title Priority Date Filing Date
DK200701150A DK200701150A (en) 1989-04-17 2007-08-13 Recombinant pox virus and vaccine against herpes virus containing this

Country Status (1)

Country Link
DK (1) DK200701150A (en)

Similar Documents

Publication Publication Date Title
Chakrabarti et al. Compact, synthetic, vaccinia virus early/late promoter for protein expression
Crabb et al. Equine herpesviruses 4 (equine rhinopneumonitis virus) and 1 (equine abortion virus)
EP0261940A3 (en) Pseudorabies vaccines and dna vectors for recombination with pox viruses
EP0220273A4 (en) Synthetic antigens for the detection of aids-related disease.
Baranowski et al. Structural and functional analysis of bovine herpesvirus 1 minor glycoproteins
EP0175787A4 (en) RECOMBINANT HERPES SIMPLEX gB-gD VACCINE.
LU91303I2 (en) Gallivac HVT IBD- recombinant live virus vHVT013-69, at least 3.0 log 10 PFU
NO20030524D0 (en) Vaccine against host cell-associated herpes virus
DK200701150A (en) Recombinant pox virus and vaccine against herpes virus containing this
ATE73495T1 (en) VACCINE AGAINST VARICELLA ZOSTER VIRUS.
BR9303226A (en) PROCESS AND VACCINE TO PRODUCE ANTIBODIES OR RECOMBINANT ADENOVIRUS-MEDIATED IMPROVEMENT
ATE73349T1 (en) HEPATITIS SURFACE ANTIGEN PARTICLE VACCINATION.
ATE102650T1 (en) MUTANTS OF INFECTIOUS BOVIN RHINOTRACCHIE VIRUS, VACCINE CONTAINING THEM, METHODS FOR THEIR PRODUCTION AND THEIR USE.
Pilaski et al. Comparative analysis of the genomes of orthopoxviruses isolated from elephant, rhinoceros, and okapi by restriction enzymes
Herrmann et al. Characterization of the feline herpesvirus genome and molecular epidemiology of isolates from natural outbreaks and latent infections
ATE93543T1 (en) VARICELLA ZOSTER VIRUS AS A LIVE RECOMBINANT VACCINE.
Patou et al. The effects of psychotropic drugs on synthesis of DNA and the infectivity of herpes simplex virus.
ATE317439T1 (en) VIRAL VACCINES
Hamelin et al. Interspecific differences between the DNA restriction profiles of canine adenoviruses
KR20230050444A (en) Recombinant poxviridae vectors expressing co-stimulatory molecules
Whalley et al. Characteristics of equine herpesvirus 1 glycoproteins expressed in insect cells
Joshi et al. Poxvirus vectors
Cabirac et al. Expression of varicella-zoster virus glycoprotein I in cells infected with a vaccinia virus recombinant
Lucin et al. Cytomegalovirus replication cycle: an overview
Fodor et al. Live recombinant vaccines--new direction in biotechnology.

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment